Skip to main content
SpringerLink
Log in

Was ist neu … Cefiderocol

What is new … cefiderocol

  • Klinische Pharmakologie
  • Published:
Die Anaesthesiologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Tacconelli E et al (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18(3):318–327

    Article  PubMed  Google Scholar 

  2. Ito A et al (2016) Siderophore Cephalosporin Cefiderocol utilizes ferric iron transporter systems for antibacterial activity against pseudomonas aeruginosa. Antimicrob Agents Chemother 60(12):7396–7401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Page MGP (2019) The role of iron and siderophores in infection, and the development of siderophore antibiotics. Clin Infect Dis 69(Suppl 7):S529–S537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Longshaw C et al (2020) In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe. JAC Antimicrob Resist 2(3):dlaa60

    Article  PubMed  PubMed Central  Google Scholar 

  5. Portsmouth S et al (2018) Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18(12):1319–1328

    Article  CAS  PubMed  Google Scholar 

  6. Wunderink RG et al (2021) Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 21(2):213–225

    Article  CAS  PubMed  Google Scholar 

  7. Bassetti M et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226–240

    Article  CAS  PubMed  Google Scholar 

  8. Paul M et al (2018) Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 18(4):391–400

    Article  CAS  PubMed  Google Scholar 

  9. Naseer S et al (2021) US Food and Drug Administration (FDA): benefit-risk considerations for cefiderocol (Fetroja(R)). Clin Infect Dis 72(12):e1103–e1111

    Article  CAS  PubMed  Google Scholar 

  10. Karakonstantis S, Rousaki M, Kritsotakis EI (2022) Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics 11(6):723. https://doi.org/10.3390/antibiotics11060723

  11. Smoke SM et al (2022) Evolution and transmission of cefiderocol-resistant Acinetobacter baumannii during an outbreak in the burn intensive care unit. Clin Infect Dis 6(3):e1261–e1265. https://doi.org/10.1093/cid/ciac647

  12. Wang Q et al (2022) Occurrence of high levels of cefiderocol resistance in carbapenem-resistant escherichia coli before its approval in China: a report from China CRE-network. Microbiol Spectr 10(3):e267021

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Anaesthesiologie, Klinikum der Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377, München, Deutschland

    Laurenz Mehringer & Michael Zoller

  2. Medizinische Klinik und Poliklinik IV, Sektion Klinische Infektiologie, LMU Klinikum Innenstadt, Pettenkoferstr. 8a, 80336, München, Deutschland

    Ulrich Seybold

Authors
  1. Laurenz Mehringer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Seybold
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Zoller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurenz Mehringer.

Ethics declarations

Interessenkonflikt

L. Mehringer gibt an Vortragshonorar von MSD Sharp & Dohme GmbH erhalten zu haben. U. Seybold und M. Zoller geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mehringer, L., Seybold, U. & Zoller, M. Was ist neu … Cefiderocol. Anaesthesiologie 72, 189–190 (2023). https://doi.org/10.1007/s00101-023-01252-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00101-023-01252-w

Search

Navigation